Trial
NCT03627052
A Study to Evaluate the Safety and Efficacy of Itacitinib in Moderate to Severe Ulcerative Colitis
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Incyte Corporation
Collaborators
—
Condition
Moderate to Severe Ulcerative Colitis
Intervention
Itacitinib
Why stopped
Study withdrawn due to lack of recruitment. No patients enrolled. No safety concerns.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-12-06